Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
78 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Hereditary Angioedema (HAE) - Pipeline Review, H1 2015', provides an overview of the Hereditary Angioedema (HAE)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hereditary Angioedema (HAE) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Hereditary Angioedema (HAE) Overview 8 Therapeutics Development 9 Pipeline Products for Hereditary Angioedema (HAE) - Overview 9 Pipeline Products for Hereditary Angioedema (HAE) - Comparative Analysis 10 Hereditary Angioedema (HAE) - Therapeutics under Development by Companies 11 Hereditary Angioedema (HAE) - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Hereditary Angioedema (HAE) - Products under Development by Companies 16 Hereditary Angioedema (HAE) - Companies Involved in Therapeutics Development 17 BioCryst Pharmaceuticals, Inc. 17 Cevec Pharmaceuticals GmbH 18 CSL Limited 19 Dyax Corp. 20 Global Blood Therapeutics, Inc. 21 iBio, Inc. 22 Isis Pharmaceuticals, Inc. 23 Pharming Group N.V. 24 Ra Pharmaceuticals, Inc. 25 Shire Plc 26 Hereditary Angioedema (HAE) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 BCX-4161 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 BCX-7353 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 BEL-0215 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 C1 esterase inhibitor (human) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 C1 esterase inhibitor (human) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 C1 esterase inhibitor (recombinant) - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 C1 esterase inhibitor (recombinant) - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CSL-312 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 DX-2930 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 icatibant acetate - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ISIS-PKKRx - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecule for Hereditary Angioedema - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Hereditary Angioedema (HAE) - Recent Pipeline Updates 58 Hereditary Angioedema (HAE) - Dormant Projects 70 Hereditary Angioedema (HAE) - Dormant Projects 70 Hereditary Angioedema (HAE) - Product Development Milestones 71 Featured News & Press Releases 71 Apr 09, 2015: Dyax to Participate in the 14th Annual Needham Healthcare Conference 71 Mar 31, 2015: Dyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930 71 Feb 24, 2015: ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels 72 Feb 02, 2015: CEVEC: CAP Derived Recombinant C1 Inhibitor Matches Berinert in Animal Study 72 Jan 08, 2015: Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest for Prophylaxis of Hereditary Angioedema 73 Dec 18, 2014: Dyax First-in-Human Trial for DX-2930 Conducted by Vince and Associates Clinical Research Featured in the Annals of Allergy, Asthma & Immunology 73 Nov 04, 2014: Pharming Confirms Receipt Of US$20 Million Milestone Payment From Salix Pharmaceuticals 74 Nov 03, 2014: Salix and Pharming Announce the Launch of RUCONEST in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE) 74 Nov 03, 2014: Dyax Announces Expansion of Phase 1b Clinical Trial for DX-2930 75 Oct 13, 2014: Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement 76 Appendix 77 Methodology 77 Coverage 77 Secondary Research 77 Primary Research 77 Expert Panel Validation 77 Contact Us 77 Disclaimer 78
List of Tables Number of Products under Development for Hereditary Angioedema (HAE), H1 2015 9 Number of Products under Development for Hereditary Angioedema (HAE) - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 11 Comparative Analysis by Late Stage Development, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Comparative Analysis by Unknown Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Hereditary Angioedema (HAE) - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2015 17 Hereditary Angioedema (HAE) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2015 18 Hereditary Angioedema (HAE) - Pipeline by CSL Limited, H1 2015 19 Hereditary Angioedema (HAE) - Pipeline by Dyax Corp., H1 2015 20 Hereditary Angioedema (HAE) - Pipeline by Global Blood Therapeutics, Inc., H1 2015 21 Hereditary Angioedema (HAE) - Pipeline by iBio, Inc., H1 2015 22 Hereditary Angioedema (HAE) - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 23 Hereditary Angioedema (HAE) - Pipeline by Pharming Group N.V., H1 2015 24 Hereditary Angioedema (HAE) - Pipeline by Ra Pharmaceuticals, Inc., H1 2015 25 Hereditary Angioedema (HAE) - Pipeline by Shire Plc, H1 2015 26 Assessment by Monotherapy Products, H1 2015 27 Number of Products by Stage and Target, H1 2015 29 Number of Products by Stage and Mechanism of Action, H1 2015 31 Number of Products by Stage and Route of Administration, H1 2015 33 Number of Products by Stage and Molecule Type, H1 2015 35 Hereditary Angioedema (HAE) Therapeutics - Recent Pipeline Updates, H1 2015 58 Hereditary Angioedema (HAE) - Dormant Projects, H1 2015 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
